Michael E Weinblatt

Michael E Weinblatt

UNVERIFIED PROFILE

Are you Michael E Weinblatt?   Register this Author

Register author
Michael E Weinblatt

Michael E Weinblatt

Publications by authors named "Michael E Weinblatt"

Are you Michael E Weinblatt?   Register this Author

100Publications

3188Reads

40Profile Views

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.

Ann Rheum Dis 2019 Sep 18;78(9):1285-1286. Epub 2019 Mar 18.

Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214860DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788881PMC
September 2019

Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs.

Arthritis Care Res (Hoboken) 2019 Sep 17. Epub 2019 Sep 17.

Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.24071DOI Listing
September 2019

In Memoriam: Shaun Ruddy, MD, 1935-2019.

Arthritis Rheumatol 2019 Aug;71(8):1215-1216

Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40916DOI Listing
August 2019

Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.

Arthritis Rheumatol 2019 Jun 29;71(6):892-900. Epub 2019 Apr 29.

Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40798DOI Listing
June 2019

Rheumatoid Nodule Formation in the Kidney: A Diagnosis of Exclusion and a Rare Manifestation of Rheumatoid Arthritis Involving the Kidney.

Kidney Int Rep 2019 May 28;4(5):745-748. Epub 2019 Jan 28.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ekir.2019.01.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506698PMC
May 2019

Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis.

BMC Rheumatol 2019 31;3. Epub 2019 Jan 31.

1Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev Hovedgade 205-207, 2730 Herlev, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s41927-019-0052-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390574PMC
January 2019

A Development and Feasibility Study of a Peer Support Telephone Program in Rheumatoid Arthritis.

J Clin Rheumatol 2018 Sep;24(6):346-349

Division of Rheumatology Immunology and Allergy Brigham & Women's Hospital Harvard Medical School Boston, MA Advocates, Inc Framingham, MA Division of Rheumatology Immunology and Allergy Brigham & Women's Hospital Harvard Medical School Boston, MA Advocate Health Care Chicago, IL Department of Psychiatry Cambridge Health Alliance Cambridge, MA Division of Rheumatology Immunology and Allergy Brigham & Women's Hospital Harvard Medical School Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000661DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699178PMC
September 2018

Transient Elastography for Monitoring for Hepatotoxicity in Rheumatoid Arthritis Patients on Long-term Methotrexate.

J Clin Rheumatol 2018 Aug 13. Epub 2018 Aug 13.

Rheumatology Fellow Beth Israel Deaconess Medical Center Harvard Medical School Clinical Fellow Boston, MA Division of Gastroenterology Department of Medicine University of British Columbia Vancouver General Hospital Vancouver, British Columbia, Canada. Division of Rheumatology Department of Medicine University of British Columbia Vancouver General Hospital Vancouver, British Columbia, Canada. Division of Rheumatology Department of Medicine Brigham and Woman's Hospital Harvard Medical School Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000885DOI Listing
August 2018

Methotrexate: who would have predicted its importance in rheumatoid arthritis?

Arthritis Res Ther 2018 05 30;20(1):103. Epub 2018 May 30.

Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-018-1599-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977479PMC
May 2018

Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.

Semin Arthritis Rheum 2018 04 13;47(5):630-638. Epub 2017 Oct 13.

Department of Medicine, Rheumatology, Immunology Brigham and Women's Hospital, and Harvard Medical School, PBB3, 75 Francis Street, Boston, MA 02115.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2017.10.009DOI Listing
April 2018

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.

Ann Rheum Dis 2018 01 8;77(1):e4. Epub 2017 Jun 8.

Department of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2017-211632DOI Listing
January 2018

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.

Arthritis Rheumatol 2018 01;70(1):49-59

Charité-University Medicine Berlin, Free University of Berlin, and Humboldt University of Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40323DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767745PMC
January 2018

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

N Engl J Med 2017 02;376(7):652-662

From the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences and the Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom (P.C.T.); the Rebecca MacDonald Centre, Mount Sinai Hospital, University of Toronto, Toronto (E.C.K.); Leiden University Medical Center, Leiden, the Netherlands (D.H.); Brigham and Women's Hospital, Boston (M.E.W.); Instituto Reumatológico Strusberg, Córdoba, Argentina (L.C.M.); Centro de Investigacion Clinica Especializada, Mexico City (J.R.G.); Ryazan Regional Clinical Cardiology Dispensary, Ryazan, Russia (S.Y.); Eli Lilly, Indianapolis (T.I., S. Beattie, V.A., C.G., T.R., D.S., W.L.M., S. de Bono); and AstraZeneca K.K., Osaka (K.E.), and the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu (Y.T.) - both in Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1608345DOI Listing
February 2017

The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.

Arthritis Rheumatol 2015 Oct;67(10):2591-600

NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.39249DOI Listing
October 2015

Editorial: the vital role of randomized controlled trials in Arthritis & Rheumatology.

Arthritis Rheumatol 2015 Oct;67(10):2555-6

Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.39258DOI Listing
October 2015

Clinical characteristics of RA patients with secondary SS and association with joint damage.

Rheumatology (Oxford) 2015 May 13;54(5):816-20. Epub 2014 Oct 13.

Department of Medicine, Massachusetts General Hospital and Division of Rheumatology, Department of Medicine, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keu400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416083PMC
May 2015

An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score.

Arthritis Res Ther 2015 Apr 13;17:83. Epub 2015 Apr 13.

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, 1620 Tremont Street, Boston, 02120, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-015-0599-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394559PMC
April 2015

Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs.

Semin Arthritis Rheum 2015 Feb 27;44(4):399-404. Epub 2014 Aug 27.

Division of Rheumatology, Immunology and Allergy, Brigham and Women׳s Hospital, Boston, MA; Division of Pharmacoepidemiology, Brigham and Women׳s Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2014.08.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843117PMC
February 2015

Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis.

J Rheumatol 2014 Dec 15;41(12):2370-8. Epub 2014 Oct 15.

From the Division of Rheumatology, Immunology and Allergy, and the Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria; Department of Rheumatology, Kameda Medical Center, Kamogawa, Chiba Prefecture, Japan.M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna; K. Yoshida, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Rheumatology, Kameda Medical Center; N.A. Shadick, MD, MPH; M.L. Frits, BA; C.K. Iannaccone, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital; T.K. Kvien, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; M.E. Weinblatt, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital; D.H. Solomon, MD, MPH, Division of Rheumatology, and Immunology and Allergy, and Division of Pharmacoepidemiology, Brigham and Women's Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.140306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843119PMC
December 2014

Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.

J Rheumatol 2014 Nov 15;41(11):2104-13. Epub 2014 Aug 15.

From the University of Alberta, Edmonton, Alberta; Augurex Life Sciences Corp., North Vancouver, British Columbia; Mount Sinai Hospital, Toronto, Ontario, Canada; Quest Diagnostics Nichols Institute, San Juan Capistrano; Stanford University Medical Center, Palo Alto, California; Hospital for Special Surgery, New York, New York; Brigham and Women's Hospital, Boston, Massachusetts, USA; Vrije Universiteit University Medical Center; Academic Medical Center/University of Amsterdam; Jan van Breemen Research Institute, Reade organization, Amsterdam; the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; University of Cambridge, Cambridge; GlaxoSmithKline, Stevenage, UK.W.P. Maksymowych, MD, Professor of Medicine, University of Alberta; S.J. Naides, MD, Quest Diagnostics Nichols Institute; V. Bykerk, MD, Hospital for Special Surgery; K.A. Siminovitch, MD, Mount Sinai Hospital; D. van Schaardenburg, MD, Jan van Breemen Research Institute; M. Boers, MD, Vrije Universiteit University Medical Center; R. Landewé, MD, Academic Medical Center/University of Amsterdam; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center; P-P. Tak, MD, Academic Medical Center/University of Amsterdam, University of Cambridge, GlaxoSmithKline; M.C. Genovese, MD, Stanford University Medical Center; M.E. Weinblatt, MD, Brigham and Women's Hospital; E.C. Keystone, MD, Mount Sinai Hospital; O.S. Zhukov, MS; R.W. Abolhosn, BS; J.M. Popov, MD, PhD, Quest Diagnostics Nichols Institute; K. Britsemmer, MD, Jan van Breemen Research Institute; A.W. van Kuijk, MD, Academic Medical Center/University of Amsterdam; A. Marotta, PhD, Augurex Life Sciences Corp.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.131446DOI Listing
November 2014

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.

J Rheumatol 2014 Nov 15;41(11):2120-8. Epub 2014 Sep 15.

From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women's Hospital, Boston, Massachusetts, USA.M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E.C. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O'Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women's Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.140238DOI Listing
November 2014

Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example.

Ann Rheum Dis 2014 Oct 11;73(10):1755-60. Epub 2014 Aug 11.

Department of rheumatology, Leiden University Medical Center, Leiden, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2014-205821DOI Listing
October 2014

Behavioral and clinical factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritis.

J Womens Health (Larchmt) 2014 Sep;23(9):771-6

1 Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School , Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jwh.2013.4658DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158949PMC
September 2014

Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis.

Chest 2014 Jul;146(1):41-50

Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Lovelace Respiratory Research Institute, Albuquerque, NM. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1378/chest.13-1394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077411PMC
July 2014

Biologic discontinuation studies: a systematic review of methods.

Ann Rheum Dis 2014 Mar 30;73(3):595-9. Epub 2013 May 30.

Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, , Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2013-203302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836605PMC
March 2014

Methotrexate in rheumatoid arthritis: a quarter century of development.

Trans Am Clin Climatol Assoc 2013 ;124:16-25

Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715949PMC
March 2014

Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al.

Ann Rheum Dis 2014 Jan 23;73(1):e5. Epub 2013 Oct 23.

Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, , Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2013-204617DOI Listing
January 2014

Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.

Clin Exp Rheumatol 2013 Jul-Aug;31(4 Suppl 78):S28-32. Epub 2013 Oct 3.

Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843121PMC
December 2013

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.

Ann Rheum Dis 2013 Sep 12;72(9):1445-52. Epub 2012 Dec 12.

Charité-University Medicine Berlin, Department of Rheumatology and Clinical Immunology Free University and Humboldt University, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2012-202450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756523PMC
September 2013

Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.

Ann Rheum Dis 2013 Jun 17;72(6):908-10. Epub 2012 Nov 17.

R&D Department, Exagen Diagnostics, Vista, California 92081, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2012-202591DOI Listing
June 2013

Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.

Arthritis Care Res (Hoboken) 2013 Mar;65(3):362-71

Division of Rheumatology and Immunology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.21847DOI Listing
March 2013

Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity.

Arthritis Care Res (Hoboken) 2012 Dec;64(12):1794-803

UAB Center for Education and Research on Therapeutics, UAB Arthritis Clinical Intervention Program, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, FOT 805D, 510 20th Street South, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.21767DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508159PMC
December 2012

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.

Rheumatology (Oxford) 2012 Dec 25;51(12):2204-14. Epub 2012 Aug 25.

Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kes150DOI Listing
December 2012

Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.

Ann Rheum Dis 2012 May 12;71(5):681-6. Epub 2011 Oct 12.

Division of Rheumatology/Section of Clinical Sciences, Alumnae Hall - Room 305, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/ard.2011.154625
Publisher Site
http://dx.doi.org/10.1136/ard.2011.154625DOI Listing
May 2012

Sustained rheumatoid arthritis remission is uncommon in clinical practice.

Arthritis Res Ther 2012 Mar 19;14(2):R68. Epub 2012 Mar 19.

Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/ar3785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446437PMC
March 2012

Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.

Arthritis Res Ther 2011 Jun 8;13(3):R83. Epub 2011 Jun 8.

Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 75 Francis Street, PBB-B3, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/ar3353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218896PMC
June 2011

The end of rheumatoid factor as we know it?

Arthritis Rheum 2011 May;63(5):1170-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.30197DOI Listing
May 2011